King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Kausar Suleman
Dr. Kausar Suleman is a Consultant Medical Oncologist based in Riyadh, Saudi Arabia, specialising in breast cancer within the Breast Cancer Centre of a national cancer referral hospital. A respected breast cancer specialist Riyadh, Saudi Arabia, she is a co-author of the 2025 Saudi Arabia breast cancer management consensus statement.
- Consultant medical oncologist dedicated to breast cancer in a specialised Breast Cancer Centre.
- Co-author of the Saudi Arabia Breast Cancer Management Consensus (2025).
- Research focus on obesity, HER2-positive invasive lobular carcinoma, and antibody-drug conjugates.
- Active contributor to national and international breast cancer meetings.
- Experienced in caring for international patients from the Gulf and Africa.
Qualifications & Credentials
Medical Degrees
- MBBS
- Residency — Internal Medicine
Fellowships & Special Training
- Fellowship — Medical Oncology
- Advanced Training — Breast Cancer
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Clinical Oncology (ASCO)
- Member — European Society for Medical Oncology (ESMO)
Areas of Expertise
Major Conditions Treated
- Early Breast Cancer
- Locally Advanced Breast Cancer
- HER2-Positive Breast Cancer
- Triple-Negative Breast Cancer (TNBC)
- Hormone Receptor-Positive Breast Cancer
- Metastatic Breast Cancer
- Invasive Lobular Carcinoma
- BRCA-Associated Breast Cancer
- Male Breast Cancer
- Breast Cancer in Pregnancy
Sub-specialties
- HER2-Targeted & ADC Therapy: Expertise in trastuzumab emtansine (T-DM1), trastuzumab deruxtecan, pertuzumab, and other HER2-targeted agents — a recognised breast cancer specialist Riyadh, Saudi Arabia for HER2-positive disease.
- Metastatic & Triple-Negative Breast Cancer: Contributes to real-world Arab-population data on sacituzumab govitecan (SG) and other antibody-drug conjugates in metastatic TNBC and HR+ mBC.
- Multidisciplinary Breast Cancer Care: Works with surgeons, radiation oncologists, pathologists, genetic counsellors, and plastic surgeons in a dedicated Breast Cancer Centre multidisciplinary board.
Advanced Procedures & Treatments
- Neoadjuvant & Adjuvant Chemotherapy
- HER2-Targeted Therapy (Trastuzumab, Pertuzumab, T-DM1, T-DXd)
- CDK4/6 Inhibitor Therapy for HR+ Breast Cancer
- Antibody-Drug Conjugates (Sacituzumab Govitecan)
- Endocrine Therapy (Tamoxifen, Aromatase Inhibitors, Fulvestrant)
- Immunotherapy for Triple-Negative Breast Cancer
- PARP Inhibitor Therapy for BRCA-Mutated Breast Cancer
- Genetic Counselling & BRCA Testing Referral
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Breast Cancer Centre, Medical Oncology Department, Cancer Centre of Excellence (Present)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Faculty — KFSHRC Medical Oncology Fellowship Programme
- Faculty — Annual KFSHRC Breast Cancer Conference
- Member — KFSHRC Breast Cancer Multidisciplinary Tumour Board
Key Achievements
- Co-author of the Saudi Arabia Breast Cancer Management Consensus (2025)
- Invited international symposium presenter on Arab population ADC toxicity
- Contributing author on HER2-positive invasive lobular carcinoma case series
- Research on obesity and breast cancer outcomes in Saudi women
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Clinical Oncology (ASCO)
- European Society for Medical Oncology (ESMO)
- International breast cancer symposium presenter
- Saudi Oncology Society
Research & Publications
Published Papers (Selected)
- Alaklabi S, Akhtar S, Al-Tweigeri T, Alsayed A, Alzahrani M, Suleman K. Management of Early and Metastatic Breast Cancer: A Consensus Statement from Oncologists in Saudi Arabia. Oncol Ther. 2025.
- Alshamsan B, Suleman K, Agha N, Abdelgawad MI, Alzahrani MJ, Elhassan T, Al-Tweigeri T, Ajarim D, Alsayed A. Association Between Obesity and Clinicopathological Profile of Patients with Newly Diagnosed Non-Metastatic Breast Cancer in Saudi Arabia. Int J Womens Health. 2022;14:373–384.
- Altarturi M, Suleman K, AlSayed A, Al-Shamsi H, Alawadhi A, Basuliamn B, Alaklabi S. Sacituzumab Govitecan Toxicity Outcomes in Arab Patients with Metastatic Breast Cancer. Cancer Res. 2024;84(9 Suppl):PO4-12-10. (SABCS 2023).
Ongoing Research & Clinical Interests
- Antibody-drug conjugate safety and efficacy in Arab women with mTNBC and HR+ mBC
- HER2-positive invasive lobular breast carcinoma outcomes
- Obesity-related outcomes in Saudi breast cancer patients
- Precision oncology and CDK4/6 inhibitors in metastatic breast cancer
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (INR) | Estimated Cost (USD) |
|---|---|---|
| Medical Oncology Consultation | ₹1,500 – ₹3,500 | $18 – $42 |
| Chemotherapy (per cycle, regimen-dependent) | ₹25,000 – ₹1,80,000 | $300 – $2,160 |
| Targeted Therapy (per month, drug-dependent) | ₹60,000 – ₹3,50,000 | $720 – $4,200 |
| Immunotherapy (per cycle) | ₹90,000 – ₹2,80,000 | $1,080 – $3,360 |
| Tumour Marker / Molecular Profiling Panel | ₹8,000 – ₹60,000 | $96 – $720 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Kausar Suleman use in Medical Oncology — Breast Cancer treatment?
Dr. Kausar Suleman uses modern breast cancer treatment tools including HER2-targeted therapy (trastuzumab, pertuzumab, T-DM1, T-DXd), antibody-drug conjugates such as sacituzumab govitecan, CDK4/6 inhibitors, immunotherapy for triple-negative disease, and PARP inhibitors for BRCA-mutated cancer. Cancer Rounds can coordinate virtual pre-travel review of pathology and imaging for international patients.
2. What conditions does Dr. Kausar Suleman specialize in treating?
Dr. Kausar Suleman specialises in early and metastatic breast cancer, HER2-positive disease, triple-negative breast cancer, hormone receptor-positive breast cancer, invasive lobular carcinoma, BRCA-associated breast cancer, and breast cancer in pregnancy — making her a trusted breast cancer specialist Riyadh, Saudi Arabia for best breast cancer treatment and second opinions.
3. How do I book an appointment with Dr. Kausar Suleman?
Appointments with Dr. Kausar Suleman can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Kausar Suleman?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Kausar Suleman, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Kausar Suleman offer second opinions for Medical Oncology — Breast Cancer cases?
Yes. Second opinion consultations with Dr. Kausar Suleman can be arranged via Cancer Rounds for patients seeking an expert Breast Cancer Medical Oncology review of diagnosis, staging, systemic therapy options, and BRCA-risk management in Riyadh, Saudi Arabia.
